Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation

Ann Hematol. 2020 Sep;99(9):2197-2199. doi: 10.1007/s00277-020-04180-6. Epub 2020 Jul 13.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Antiemetics / administration & dosage
  • Antiemetics / therapeutic use*
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Induction Chemotherapy
  • Male
  • Melphalan / adverse effects*
  • Middle Aged
  • Multiple Myeloma / therapy*
  • Nausea / chemically induced
  • Nausea / prevention & control*
  • Palonosetron / administration & dosage
  • Palonosetron / therapeutic use*
  • Prospective Studies
  • Pyridines / administration & dosage
  • Pyridines / therapeutic use*
  • Transplantation Conditioning / adverse effects*
  • Transplantation, Autologous
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Pyridines
  • Palonosetron
  • netupitant
  • Dexamethasone
  • Melphalan